


Modifying proteins to combat disease

January 24 2013, by Mona Mort



Structure of the human PRMT5:MEP50 hetero-octameric complex bound to a substrate peptide and a cofactor analog. Cartoon representations of the PRMT5 monomers are colored blue, green, wheat, and yellow, while the MEP50 molecules are in red. Highlighted in stick representation are the substrate peptide derived from histone H3 in magenta, and the cofactor analog in orange.

Transmitting from one generation to the next the genetic message encoded in DNA is a well-understood concept in biology. There is now increasing awareness that chemical modifications of DNA and associated proteins are also transmitted across generations, and these changes are critical in determining the way the genetic message is read.

Detailed understanding of the structures of the proteins that effect these changes is therefore highly coveted information. Thanks to the efforts of a research team from Eli Lilly and Company, with the help of the Lilly Research Laboratories Collaborative Access Team (LRL-CAT) beamline 31-ID at the U.S. Department of Energy Office of Science's Advanced Photon Source, the structure of an important methylation enzyme is now known. The results of this research can be utilized to provide new direction and focus in the race to create drugs to combat disease, especially cancer.

A prime example of chemical modifications is the addition of a [methyl group](#) (methylation) to the side-chain of arginine residues of proteins, dramatically altering their activity and interactions. Aberrant methylation has been linked to a wide variety of diseases, most notably cancer.

The Lilly research team investigated a protein from a group of enzymes known as protein arginine methyltransferases (PRMTs), which play important roles in cell signaling, [gene regulation](#), and the transport of proteins and [nucleic acids](#).

The team focused on PRMT5, which had been previously shown to be part of a complex of partner proteins that help regulate its function and specificity. Because enhanced levels of PRMT5 have been observed in various [types of cancer](#), it is a focus of anti-cancer drug research.

In particular, the researchers were interested in how PRMT5 interacts with methylosome protein 50 (MEP50), known to be a critical mediator of binding with other members of the protein complex and with substrates. Phosphorylation of either MEP50 or of PRMT5 itself can control methyltransferase activity of PRMT5. Activation of the methyltransferase activity of PRMT5 was known to prolong survival of tumor cells while mutants that disrupt its association with MEP50 inhibited that methyltransferase activity.

Since MEP50 activity has been linked especially to ovarian and prostate cancer, details of its structure and modes of interaction with PRMT5 and other members of the binding complex are prime targets of current research.

The research team determined a definitive structure for PRMT5 in interaction with MEP50, bound to a peptide derived from histone H4. The team combined data from chromatography, sedimentation analysis, enzymology, and x-ray crystallography using data collected at 31-ID to elucidate the structure and activity of the PRMT5:MEP50 complex.

The resulting structure yielded a surprise: a hetero-octameric complex that shows close interaction between a seven-bladed propeller-like MEP50 and the N-terminal domain of PRMT5. The structure offers a clear view of how substrate recognition occurs and points the way toward promising targets for drug design.

The researchers were able to compare their data from human PRMT5 with newly published data on PRMT5 from the nematode worm, which shows 31% sequence identity with human PRMT5. The dimeric PRMT5 complex in the nematode was strikingly different than the large octameric human PRMT5, in which four molecules of PRMT5 and four of MEP50 form the functional core of the PRMT5 complexes.

This important octameric structural core in human PRMT5 is proposed as the main driver of interactions with partner proteins to create a multimeric complex of subunits with different specificities and functions. In addition, when compared with what was previously known about PRMTs, important differences in the three-dimensional structure of PRMT5 and how it interacts with MEP50 were discovered.

Such critical details will be all-important in anti-cancer drug design. The structural data also allow the role of MEP50 to be expanded by

suggesting its importance in recruiting substrates and partners to PRMT5.

By providing a detailed [structure](#) of PRMT5 in interaction with MEP50, the research team has revealed critical insights about posttranslational methylation and identified promising target sites for drugs to combat cancer and other diseases related to methylation processes.

More information: Antonysamy, S. et al. Crystal structure of the human PRMT5:MEP50 complex, *Proc. Natl. Acad. Sci. USA* 109(44), 17960 (October 30, 2012). [DOI:10.1073/pnas.1209814109](https://doi.org/10.1073/pnas.1209814109)

Provided by Argonne National Laboratory

Citation: Modifying proteins to combat disease (2013, January 24) retrieved 23 April 2024 from <https://phys.org/news/2013-01-proteins-combat-disease.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.